Mechanistically, FTO increases metabolic reprogramming and survival of VHL-deficient ccRCC cells by targeting SLC1A5 in a hypoxia-inducible factor (HIF)-independent way (Xiao et al., 2020). The gene discussed is FTO; the disease is nonpapillary renal cell carcinoma.